Indications & Dose: ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS PO Adult Tablet: 500mg BID 7-14 days, ER: 1g/day 7 days, suspension: 500mg BID 1 wk | ACUTE OTITIS MEDIA PO Child 12-18 yr: 250mg BID 7 days, increased to 500mg BID 14 days in severe conditions | IV Child Inf: 12-18 yr: 500mg BID | ACUTE SINUSITIS PO Adult Conventional tablets/Suspension: 500mg BID 14 days, ER: 1g/day 14 days Child 7.5mg/kg BID 10 days | COMMUNITY-ACQUIRED PNEUMONIA PO Adult Conventional tablets/Suspension: 250mg BID 14 days, ER: 1g/day 7days Child 7.5mg/kg BID 10 days | DUODENAL ULCER PO Adult Conventional tablets/suspension: 500mg TID 2 wk given with omeprazole (40mg/day 2 wk, then 20mg/day for next 2 wk) or 500mg BID 10/14 days given with amoxicillin (1g BID 10/14 days) & lansoprazole (30mg BID 10/14 days) or 500mg BID 10 days with amoxicillin (1g twice BID 10 days) & omeprazole (20mg BID 10 days, then 20mg/day for next 18 days) | H.PYLORI INFECT PO Adult Conventional tablets/suspension: 500mg TID 2 wk given with omeprazole (40mg/day 2 wk) or 500mg BID 10/14 days given with amoxicillin (1g BID 10/14 days) & lansoprazole (30mg BID 10/14 days) or 500mg BID 10 days with amoxicillin (1g BID 10 days) & omeprazole (20mg BID 10 days) | MYCOBACTERIUM AVIUM COMPLEX INFECT PO Adult Conventional tablets/Suspension: 500mg BID with ethambutol (15mg/kg/day) with/without third drug Child 7.5-15mg/kg, max 500mg BID with ethambutol (15-2 mg/kg/day with/without rifabutin | PO Adult 500mg BID with ethambutol (15mg/kg/day) with/without rifabutin (300mg/day) prevention of recurrurence Child 7.5 mg/kg, max 500mg BID with ethambutol (15mg/kg/day ) with/without rifabutin (5mg/kg/day) prevention of recurrurence | PO Adult Conventional tablets/Suspension: 500mg BID primary Prophylaxis in HIV Infect Child 7.5mg/kg BID, max 500mg primary Prophylaxis in HIV Infect | PHARYNGITIS/TONSILLITIS PO Adult Conventional tablets/ suspension: 250mg BID 10 days Child Conventional tablets/ suspension: 7.5mg/kg BID 10 days | SKIN/SKIN STRUCTURE INFECT Uncomplicated PO Adult Conventional tablets/Suspension: 250mg BID 7-14 days Child 12-18 yr: 250mg BID 7 days, increased to 500mg BID 14 days in severe conditions | IV Child Inf: 12-18 yr: 500mg BID

Precautions: Coronary artery disease, myasthenia gravis, severe renal impairment, elderly, hepatic impairment

ADR: Serious: Interstitial nephritis, renal failure, thrombophlebitis, arthralgia, myalgia, hypoglycemia, leucopenia, thrombocytopenia, increased PT, Others: GI disturbances, smell & taste disturbances, stomatitis, glossitis, tongue & tooth discoloration, headache, pain at Inj site

DDI: Serious Zidovudine bioavailability reduced, Antihistamines causes QT interval prolongation & leads to life-threatening Torsade de pointes arrhythmias, Delavirdine increases drug levels, Coumarins increases risk of bleeding, Rifabutin increases risk of uveitis & neutropenia, Amiodarone leads to additive effects on QT interval, Glipizide/Glibenclamide leads to hypoglycemia, Itraconazole/Cabergoline levels increased, Digoxin levels increases leads to toxicity, PPIs levels raises, Ergotamine/Dihydroergotamine/Nifedipine/Verapamil toxicity raises

Diet: With/without food (IR & Susp), with food (ER)

Monitor: CBC, BUN, creatinine